Solifenacin treatment for neurogenic detrusor overactivity: patient-reported outcomes (PROs) from the randomised clinical trial SONIC

De Ridder D1, Amarenco G2, Finazzi-Agrò E3, Angulo J4, Kurenkov A5, Wright M6, Fagertun H7, Compion G6

Abstract Category

Detrusor Overactivity

Abstract 333
Non Discussion Poster
Scientific Non Discussion Poster Session 31
1. University Hospitals KU Leuven, Leuven, Belgium, 2. Hôpital Tenon, Paris, France, 3. University Tor Vergata, Rome, Italy, 4. Hospital Universitario de Getafe, Getafe, Spain, 5. Medical Research Institute, Saint Petersburg, Russia, 6. Astellas Pharma Europe, Staines, UK, 7. Astellas Pharma Global Development, Leiderdorp, The Netherlands